Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?

Hospices Civils de Lyon150 enrolled

Overview

The potential clinical implications of this study are to optimise the selection of a population at risk for developing a diabetic cardiomyopathy among diabetic patients in order to develop early therapeutic strategies to prevent the left ventricular remodelling. Therefore, the originality of this project is to hypothesize that : * Diabetes mellitus is often associated with a premature aging syndrome * Cellular senescence may potentiate the mechanisms that are involved in decreasing myocardial contractility in DM and, * DM associated to premature aging may increase the risk of developing a cardiomyopathy Thus, the modulation of telomerase activity and the control of telomere length, together with the attenuation of the formation of reactive oxygen species, might represent important new targets in order to develop therapeutic tools in prevention of diabetic cardiomyopathy.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

150

Conditions

Type 2 Diabetes Mellitus

Interventions

Eligibility

Sex: ALLMin age: 40 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 Diabetes mellitus * 40 \< Age \< 55 years old * oral antidiabetic or insulin treatment * No symptoms * Sinus rhythm * no sign or history of heart disease * LVEF \> 55% * Absence of regional left ventricular motion abnormalities. Exclusion Criteria: * absence of sinus rhythm, * silent ischemia defined as positive exercise test or positive stress echocardiography, * history of cardiomyopathy or CAD, * valvular heart disease hemodynamically significant, * severe renal insufficiency defined as creatinine clearance \< 30 mL/min, * echocardiographic images unsuitable for quantification, * type 1 diabetes mellitus, * Important diabetes mellitus imbalance defined as glycated hemoglobin \> 9% or glycemia \> 3g/L uncontrolled hypertension (\> 180/100 mmHg).

Outcomes

Primary Outcomes

Telomere shortening

Investigate whether biomarkers for senescence determined from blood samples, including telomere shortening and telomerase activity in diabetic patients have an impact of left ventricular remodelling as compared with age-matched controls and biological aged control subjects.

Time frame: 36 months

Secondary Outcomes

Dysfunction by speckle tracking imaging

Study the incidence of subtle regional myocardial dysfunction by speckle tracking imaging (longitudinal and radial systolic strain)

Time frame: 36 months

Determine the predictive value of alteration

Determine the predictive value of alteration : Proteinuria, glycosylated haemoglobin, diabetes mellitus duration, blood pressure, BNP dosage, MRI diagnoses

Time frame: 36 months

Cardiovascular events

Investigate the predictive value of all those factors( telomere shortening, telomerase activity, echo abnormalities) on cardiovascular events including MI, HF, arrhythmia; ACV

Time frame: 36 months

Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes